GCG and Insulin resistance: Glucagon-like peptide-1 (GLP-1) agonists are a treatment option for patients with insulin resistance and cardiovascular disease, demonstrating improvement in a broad range of cardiovascular outcomes and metabolic endpoints in a series of landmark studies [5,6,7].